Articles

If you build it, they will come

Vetter to invest $320 million in manufacturing plant
Written byLori Lesko
| 3 min read

RAVENSBURG, Germany—Taking a huge step toward expanding its global footprint, German biopharmaceutical company Vetter stands poised to pour $320 million into the development of 18 acres in Des Plaines, Ill., for the construction of a 1.2 million-square-foot manufacturing plant, the German company’s second and largest U.S. site, thus strengthening its strategic partnership plan. Vetter’s economic development agreement with the state of Illinois is expected to create up to 500 jobs designed to meet the market supply needs of commercialized drugs by 2030. Although the deal, forged July 12, appears to be a go, final approval rests with Des Plaines City Council.

If the project goes as planned, the new facility would complement Vetter’s existing site at the Illinois Science+Technology Park in nearby Skokie, Ill., which has approximately 70 employees.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue